Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIGHT Study: Clazakizumab for Mobility in Older Adults
NCT05727384Phase 2Completed
- Start
- Aug 2023
- Primary completion
- Jan 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of clazakizumab in inflammation, frailty syndrome. Started Aug 2023; status: completed.
02
Drugs
clazakizumab
03
Conditions
inflammationfrailty syndrome
Beyond the preview
Go deeper on NCT05727384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05727384.